Glaxo Contribution To SmithKline Merger Shrinks With Lotronex Withdrawal
Executive Summary
Glaxo Wellcome appears to have managed the withdrawal of Lotronex without jeopardizing its pending merger with SmithKline Beecham.
You may also be interested in...
Glaxo Lotronex Withdrawal Follows Failed Risk Management Negotiations
Glaxo Wellcome's withdrawal of Lotronex suggests that hurdles remain in FDA's efforts to expand the use of risk management programs for approved products.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials